Australia - engelsk - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - erythromycin, quantity: 250 mg - capsule, enteric - excipient ingredients: gelatin; povidone; cellacefate; lactose monohydrate; monobasic potassium phosphate; diethyl phthalate; erythrosine; indigo carmine; carbon black; purified water; shellac; sunset yellow fcf - indications as at 22 may 2003: eryc is indicated in children and adults for the treatment of the following conditions: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta haemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta hemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae), acute and chronic bronchitis, pneumonia. sinusitis caused by streptococcus pneumoniae, streptococcus pyogenes. otitis media due to streptococcus pneumoniae, streptococcus pyogenes. respiratory tract infections due to mycoplasma pneumonia (eaton's agent). skin, and skin structure infections of mild to moderate severity caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). bordetella pertussis: erythromycin produces early elimination of the causative organism from the nasopharynx although the clinical course of the disease is not altered; therapeutic doses should be continued for at least 10 days. diphtheria: as an adjunct to antitoxin infections due to corynebacterium diphtheriae, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum. non-gonococcal urethritis: chlamydia trachomatis and ureaplasma urealyticum have been shown to be sensitive to erythromycin and clinical studies have demonstrated its efficacy in urethritis due to these organisms. a minimum of 10 days therapy appears to be required. chlamydia trachomatis infection (excluding non-gonococcal urethritis): erythromycin has been shown to be effective in the treatment of trachoma or inclusion-body conjunctivitis and pneumonia in infants caused by chlamydia trachomatis. campylobacter fetus (subspecies) jejuni: infections due to this organism when antibiotic therapy is indicated. primary syphilis caused by treponema pallidum: erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. in the treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the followup after therapy. legionnaires' disease caused by legionella pneumophila: although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. prevention of initial attacks of rheumatic fever: penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta - haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin allergic patients. a therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended by the american heart association in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). prevention of bacterial endocarditis: although no controlled clinical efficacy trials have been conducted, oral erythromycin has been suggested by the american heart association and the american dental association in a regimen for prophylaxis against bacterial endocarditis in patients sensitive to penicillin who have congenital heart disease, or rheumatic or other acquired valvular heart disease when they undergo dental or surgical procedures of the upper respiratory tract. erythromycin is n ot suitable prior to genitourinary or gastrointestinal tract surgery.

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

elanco australasia pty ltd - clorsulon; ivermectin - parenteral liquid/solution/suspension - clorsulon ungrouped active 100.0 mg/ml; ivermectin anthelmintic active 10.0 mg/ml - parasiticides - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - barber's pole worm - haemonchus placei | black scour worm - trichostrongylus spp. | brown stomach worm - ostertagia lyrata | cattle tick | chorioptic mange mite | eyeworm - thelazia spp. | hookworm - bunostomum phlebotomum | intestinal threadworm - s. papillosus | large roundworm - toxocara vitulorum | liver fluke | longnosed cattle louse | lungworm - dictyocaulus viviparus | mange mite - s. scabiei var. bovis | nematodirus helvetianus | nodule worm - oesophagostomum radiatum | screw worm fly - chrysomya bezziana | shortnosed cattle louse | small brown stomach worm - o. ostertagi | small brown stomach worm-ostertagia spp. | small intestinal worm - cooperia spp. | stomach hair worm | thin necked intestinal worm-n. spathiger | tubercle-bearing louse | whipworm (adult) - trichuris spp. | including inhibited stages | large lungworm | little blue sucking louse | long-nosed sucking louse | screw worm fly - larval stages | short nosed sucking louse | teladorsagia | thin necked intestinal worm | thin necked intestina

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

imtrade australia pty ltd - diflufenican - suspension concentrate - diflufenican anilide/aniline-nicotinanilide active 500.0 g/l - herbicide - clover pasture | field pea | lentil | lupin | poppy oilseed | drug poppy | oilseed poppy | opium poppy | pulse | subterranean cl - amsinckia - suppression | capeweed - suppression | charlock | chickweed - suppression | corn gromwell - suppression | crassula - suppression | deadnettle | hedge or wild mustard | hyssop loosestrife - suppression | indian hedge mustard | marshmallow - suppression | mouse-ear chickweed - suppression | night-scented stock - suppression | paterson's curse - suppression | pheasant's-eye or adonis | prickly lettuce | rough poppy - suppression | shepherd's purse - suppression | skeleton weed - suppression | sorrel - suppression | speedwell (v. hederifolia) - suppression | stinging nettle - suppression | toad rush - suppression | turnip weed | wild radish or radish weed | wild turnip - brassica tournefortii | wireweed, hogweed - suppression | adonis annua | adonis dentatus | brassica kaber | brassica sinapistrum | buglossoides arvense | crambling mustard | giant mustard | hedge mustard | henbit deadnettle | iron weed | ivyleaf speedwell | ivyleaved speedwell | jointed charlock | knotweed | marsh mallow | mouse-eared

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

evergreen garden care australia pty ltd - metaldehyde - pellet (eg snail bait) - metaldehyde aldehyde active 15.0 g/kg - molluscicide - garden - common slug | snail | bradybaena similaris | deroceras caruanae | helix aspersa | sigmurethra | theba pisana

Australia - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wsd agribusiness pty ltd - piperonyl butoxide; diazinon; pyrethrin - topical dust, powder - piperonyl butoxide benzodioxole active 0.8 g/kg; diazinon organophosphorus active 15.0 g/kg; pyrethrin pyrethroid-pyrethrin active 1.0 g/kg - parasiticides - animal | cattle | goat | pigs | sheep | beef | billy | boar | bos indicus | bos taurus | bovine | buck | buffalo | bull | bulloc - fly strike | wound dressing | blowfly strike | body & crutch strike | body strike only | crutch strike | poll strike | poultice dressing

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg - injection, solution - excipient ingredients: phenol; poloxamer; sodium hydroxide; phosphoric acid; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; water for injections; glycine - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 3.3 mg/ml - injection - excipient ingredients: poloxamer; dibasic sodium phosphate heptahydrate; benzyl alcohol; sodium hydroxide; monobasic sodium phosphate; mannitol; water for injections; phosphoric acid - omnitrope is intended for long term treatment of children (above three years of age with growth disturbance due to insufficient secretion of pituitary growth hormone; growth disturbance associated with gonadal dysgenesis (turner's syndrome); & growth disturbance associated with chronic renal insufficiency.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; phenol; phosphoric acid; water for injections; sodium chloride; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; poloxamer - omnitrope is intended for the long term treatment of children (above three years of age) with:,- growth disturbance due to insufficient secretion of pituitary growth hormone,- growth disturbance associated with gonadal dysgenesis (turner syndrome),- growth disturbance associated with chronic renal insufficiency.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg - injection, solution - excipient ingredients: phenol; poloxamer; sodium hydroxide; phosphoric acid; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; water for injections; glycine - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - somatropin -